267 related articles for article (PubMed ID: 26379424)
21. Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis.
Mochizuki H; Matsubara A; Teishima J; Mutaguchi K; Yasumoto H; Dahiya R; Usui T; Kamiya K
Biochem Biophys Res Commun; 2004 Jul; 320(3):656-63. PubMed ID: 15240098
[TBL] [Abstract][Full Text] [Related]
22. Bone marrow micrometastasis is associated with both disease recurrence and poor survival in surgical patients with node-negative non-small-cell lung cancer: a meta-analysis.
Deng XF; Liu QX; Zhou D; Min JX; Dai JG
Interact Cardiovasc Thorac Surg; 2015 Jul; 21(1):21-7. PubMed ID: 25883247
[TBL] [Abstract][Full Text] [Related]
23. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model.
Shanmugam MK; Manu KA; Ong TH; Ramachandran L; Surana R; Bist P; Lim LH; Kumar AP; Hui KM; Sethi G
Int J Cancer; 2011 Oct; 129(7):1552-63. PubMed ID: 21480220
[TBL] [Abstract][Full Text] [Related]
25. CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer.
Stanisavljević L; Aßmus J; Storli KE; Leh SM; Dahl O; Myklebust MP
Tumour Biol; 2016 Jun; 37(6):7441-52. PubMed ID: 26678887
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of miR-21 for prostate cancer: a systematic review and meta-analysis.
Stafford MYC; Willoughby CE; Walsh CP; McKenna DJ
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34931228
[TBL] [Abstract][Full Text] [Related]
27. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
28. Elevated expression of CXCR4 and correlation with clinicopathological features and prognosis of non-small cell lung cancer patients: a meta-analysis.
Wang H; Xie F; Hu Z; Chen L
Genet Mol Res; 2015 Dec; 14(4):17893-903. PubMed ID: 26782435
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of chemokine receptor CXCR4 predicts lymph node metastatic risk in patients with melanoma: A systematic review and meta-analysis.
Alimohammadi M; Rahimi A; Faramarzi F; Alizadeh-Navaei R; Rafiei A
Cytokine; 2021 Dec; 148():155691. PubMed ID: 34464923
[TBL] [Abstract][Full Text] [Related]
30. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer.
Kaifi JT; Yekebas EF; Schurr P; Obonyo D; Wachowiak R; Busch P; Heinecke A; Pantel K; Izbicki JR
J Natl Cancer Inst; 2005 Dec; 97(24):1840-7. PubMed ID: 16368946
[TBL] [Abstract][Full Text] [Related]
31. The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis.
Qiu L; Xu Y; Xu H; Yu B
BMC Cancer; 2022 Jun; 22(1):681. PubMed ID: 35729596
[TBL] [Abstract][Full Text] [Related]
32. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
33. Prognosis and Clinicopathology of CXCR4 in Colorectal Cancer Patients: a Meta-analysis.
Li LN; Jiang KT; Tan P; Wang AH; Kong QY; Wang CY; Lu HR; Wang J
Asian Pac J Cancer Prev; 2015; 16(9):4077-80. PubMed ID: 25987090
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological significance of CXCR4 expression in renal cell carcinoma: a meta-analysis.
Tang B; Tang F; Li Y; Yuan S; Li B; Wang Z; He S
Ann Surg Oncol; 2015 Mar; 22(3):1026-31. PubMed ID: 25249257
[TBL] [Abstract][Full Text] [Related]
35. Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA).
Cao Z; Wei L; Zhu W; Yao X
Medicine (Baltimore); 2018 Mar; 97(12):e0182. PubMed ID: 29561434
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator‑activated receptor γ agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4/CXCL12 axis.
Qin L; Gong C; Chen AM; Guo FJ; Xu F; Ren Y; Liao H
Mol Med Rep; 2014 Aug; 10(2):695-700. PubMed ID: 24842333
[TBL] [Abstract][Full Text] [Related]
37. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer.
Yang B; Liu Z; Ning H; Zhang K; Pan D; Ding K; Huang W; Kang XL; Wang Y; Chen X
Cancer Biomark; 2016 Jul; 17(2):223-30. PubMed ID: 27434290
[TBL] [Abstract][Full Text] [Related]
39. [Correlation of CXCR4/CXCL12 overexpression to lymph node metastasis and chronic inflammation in cervical adenocarcinoma].
Wei M; Liang LZ; Zhang CQ; Xiong Y; Zhang Y; Shen Y; Li JQ
Ai Zheng; 2007 Mar; 26(3):298-302. PubMed ID: 17355795
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of Muc5AC in gastric cancer: A meta-analysis.
Zhang CT; He KC; Pan F; Li Y; Wu J
World J Gastroenterol; 2015 Sep; 21(36):10453-60. PubMed ID: 26420972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
